## CCP modules of known structure ${ }^{\text {a }}(\mathbf{2 3} / \mathbf{1 0} / \mathbf{2 0 0 9})$

| CCP-containing protein | SwissProt Accession no. | PDB code(s) | Modules solved |
| :---: | :---: | :---: | :---: |
| Complement receptor 1 (CD35) | P17927 | $\begin{aligned} & 1 \mathrm{GKN}^{\mathrm{NMR}} 15,16 ; 1 \mathrm{GKG}^{\mathrm{NMR}} 16,17 \\ & 1 \mathrm{PPQ}^{\mathrm{NMR}} 16 \end{aligned}$ | $\begin{aligned} & 15,16,17 \text { (of } \\ & 30) \end{aligned}$ |
| Complement receptor 2 (CD21) | P20023 | $1 \mathrm{GHQ}^{\mathrm{XR}} 1,2^{\mathrm{b}} ; 1 \mathrm{LY} 2^{\mathrm{XR}} 1,2$ | 1,2 (of 15 or 16) |
| Decay accelerating factor (CD55) | P78361 | $\begin{aligned} & 1 \mathrm{H} 03^{\mathrm{XR}} 3,4 ; 1 \mathrm{H}_{1} 4^{\mathrm{XR}} 3,4 ; 1 \mathrm{H}_{2} \mathrm{P}^{\mathrm{XR}} 3,4 ; \\ & 1 \mathrm{H} 2 \mathrm{Q}^{\mathrm{xR}} 3,4 ; 1 \mathrm{UOT}^{\mathrm{XR}} 3,4 ; 1 \mathrm{OJV}^{\mathrm{XR}} 1-4 ; \\ & 1 \mathrm{OJW}^{\mathrm{XR}} 1-4 ; 1 \mathrm{OJ}^{\mathrm{xR}} 1-4 ; 1 \mathrm{OK}_{1} 1^{\mathrm{XR}} 1-4 ; \\ & 1 \mathrm{OK}^{\mathrm{XR}} 1-4 ; 1 \mathrm{OK} 3^{\mathrm{xR}} 1-4 ; 1 \mathrm{OK}^{\mathrm{XR}} 1-4 ; \\ & 1 \mathrm{NWV}^{\mathrm{NMR}} 2,3 \end{aligned}$ | 1, 2, 3, 4 (of 4) |
| Membrane cofactor protein (CD46) | P15529 | $1 \mathrm{CKL}^{\mathrm{XR}} 1,2 ; 2 \mathrm{O} 39^{\mathrm{XR}} 1,2^{\text {c }}$ | 1, 2 (of 4) |
| Factor H | P08603 | $\begin{aligned} & 2 \mathrm{RLP}^{\mathrm{NMR}} 1,2 ; 2 \mathrm{RLQ}^{\mathrm{NMR}} 2,3 ; 2 \mathrm{WII}^{\mathrm{XR}} 1-4^{\mathrm{r}} ; \\ & 2 \mathrm{~W}^{\mathrm{xR}} 6,7^{\mathrm{s}} ; 2 \mathrm{~W}^{\mathrm{XR}} 6,7^{\mathrm{s}} ; 2 \mathrm{UWN}^{\mathrm{XR}} 6- \\ & 8\left(\mathrm{H}^{\mathrm{X}} 42^{\mathrm{p}} ; 2 \mathrm{~V}^{\mathrm{XR}} 6-8(\mathrm{H} 402)^{\mathrm{p}} ;\right. \\ & 2 \mathrm{JGW}^{\mathrm{NMR}} 7(\mathrm{H} 402) ; 2 \mathrm{JGX}^{\mathrm{NMR}} 7(\mathrm{Y} 402) ; \\ & 2 \mathrm{KMS}^{\mathrm{NMR}} 12,13 ; 1 \mathrm{HFH}^{\mathrm{NMR}} 15,16 ; \\ & 1 \mathrm{HFI}^{\mathrm{NMR}} 15 ; 1 \mathrm{HCC}^{\mathrm{NMR}} 16 ; \\ & 2 \mathrm{BZM}^{\mathrm{NMR}} 19,20 ; 2 \mathrm{GI}^{\mathrm{XR}} 19,20 \end{aligned}$ | $\begin{aligned} & 1,2,3,4,5^{\mathrm{d}}, 6, \\ & 7,8,12,13,15, \\ & 16,19,20 \text { (of } \\ & 20) \end{aligned}$ |
| C4b-binding protein $\alpha$-chain | P04003 | $2 \mathrm{~A} 55^{\mathrm{NMR}} 1,2$ | 1,2(of 8) |
| Vaccinia virus complement control protein (VCP) | P10998 | $\begin{aligned} & 1{\mathrm{G} 40^{\mathrm{XR}} 1-4 ; 1 \mathrm{G}_{4} 4^{\mathrm{XR}} 1-4 ; 1 \mathrm{VVC}^{\mathrm{NMR}} 3,4 ;}_{1 \mathrm{VVD}^{\mathrm{NMR}} 3,4 ; 1 \mathrm{VVE}^{\mathrm{NMR}} 3,4 ;}^{1 \mathrm{E} 5 \mathrm{G}^{\mathrm{NMR}} 2,3 ; 1 \mathrm{RID}^{\mathrm{XR}} 1-4^{\mathrm{e}} ; 1 \mathrm{Y}_{2}^{\mathrm{XR}} 1-4^{\mathrm{f}}} \end{aligned}$ | 1, 2, 3, 4 (of 4) |
| Factor B | P00751 | $2 \mathrm{OK} 5^{\mathrm{XR}} 1-3^{\mathrm{g}}, 3 \mathrm{HRZ}^{\mathrm{XR}} 1-3^{\mathrm{t}}, 3 \mathrm{HS} 0^{\mathrm{XR}} 1-3^{\mathrm{t}}$ | 1,2, 3 (of 3) |
| C2 | P06681 | $3 \mathrm{ERB}^{\mathrm{XR}} 1-3$ | 1, 2, 3 (of 3) |
| C1r | P00736 | $\begin{aligned} & 1 \mathrm{GPZ}^{\mathrm{XR}} 1,2^{\mathrm{h}} ; 2 \mathrm{QY} 0^{\mathrm{XR}} 1,2^{\mathrm{h}} ; 1 \mathrm{MD} 7^{\mathrm{XR}} 2^{\mathrm{h}} ; \\ & 1 \mathrm{MD} 8^{\mathrm{xR}} 2^{\mathrm{h}} \end{aligned}$ | 1,2(of 2) |
| C1s | P09871 | $1 \mathrm{ELV}^{\mathrm{XR}} 2^{\mathrm{h}}$ | 2 (of 2) |
| MASP-1 | P48740 | $3 \mathrm{GOV}^{\mathrm{xR}} 1,2^{\mathrm{h}}$ | 1,2(of 2) |
| MASP-2 | O00187 | $1 \mathrm{Q} 3 \mathrm{X}^{\mathrm{XR}} 2^{\mathrm{h}} ; 1 \mathrm{ZJK}^{\mathrm{XR}} 1,2^{\mathrm{h}}$ | 1, 2 (of 2) |
| Apolipoprotein H ( $32-\mathrm{GPI}$ ) | P02749 | $\begin{aligned} & 1 \mathrm{C}_{1 \mathrm{Z}^{\mathrm{XR}} 1-5 ; 1 \mathrm{QUB}^{\mathrm{XR}} 1-5 ; 1 \mathrm{G} \mathrm{~F}^{\mathrm{NMR}} 5 ;}^{1 \mathrm{G}^{\mathrm{NMR}} 5} \end{aligned}$ | $\begin{aligned} & 1,2,3,4,5(\mathrm{of} \\ & 5)^{\mathrm{i}} \end{aligned}$ |
| GABA-B receptor $1 \alpha^{j}$ | Q9Z0U4 | $1 \mathrm{SS}^{\mathrm{NMR}} 2$ (cis X-Pro form); $1 \mathrm{SRZ}^{\mathrm{NMR}} 2$ (trans X-Pro form) | $2(\text { of } 2)^{\text {k }}$ |
| Corticotrophin releasing factor receptor $2 \beta^{1}$ | Q60748 | $1 \mathrm{U} 34^{\mathrm{NMR}} 1 ; 2 \mathrm{JNC}^{\text {NMR }} 1^{\mathrm{m}} ; 2 \mathrm{JND}^{\text {NMR }} 1^{\mathrm{m}}$ | $1(\text { of } 1)^{\text {n }}$ |
| Interleukin-2 receptor $\alpha$-chain ${ }^{\circ}$ | P01589 | $1 \mathrm{Z} 92^{\mathrm{XR}} 1,2 ; 2 \mathrm{~B} 5 \mathrm{I}^{\mathrm{XR}} 1,2 ; 2 \mathrm{ERJ}^{\mathrm{XR}} 1,2$ | 1,2(of 2) |
| Interleukin-15 receptor $\alpha$-chain | Q13261 | $\begin{aligned} & 2 \mathrm{ERS}^{\mathrm{NMR}} 1 ; 2 \mathrm{PSM}^{\mathrm{XR}} 1^{\mathrm{q}, 1} ; 2 \mathrm{Z}_{3} \mathrm{R}^{\mathrm{XR}} 1^{\mathrm{q}} ; \\ & 2 \mathrm{Z} 3 \mathrm{Q}^{\mathrm{XR}} 1^{\mathrm{q}} \end{aligned}$ | 1 (of 1) |


| CCP-containing protein | SwissProt <br> Accession <br> no. | PDB code(s) | Modules solved |
| :--- | :--- | :--- | :--- |
| Seizure 6-like protein isoform 3 | Q9BYH1 | $2 \mathrm{YRA}^{\mathrm{NMR}_{3}}$ | 3 (of 5) |
| CUB and sushi domain-containing <br> protein 1 (CSMD1) | Q96PZ7 | $2 \mathrm{EHF}^{\mathrm{NMR}} 3$ | 3 (of 28) |
| Complement receptor 1- <br> related/gene protein y (CRRY) | Q 63135 | $2 \mathrm{VYB}^{\mathrm{XR}} 1-4^{\mathrm{u}}$ | $1,2,3,4$ (of 6 <br> or 7) |

[^0]
[^0]:    ${ }^{\text {a }}$ Derived from the PDB (http://www.rcsb.org/pdb) IDs are followed by a coded footnote (see below) and the relevant module numbers. Citations may be found at the PDB. NMR: structure solved in solution using NMR; XR: structure solved by X-ray diffraction.
    ${ }^{\mathrm{b}}$ Solved in complex with C3d.
    ${ }^{\text {c }}$ Solved in complex with adenovirus type 11 knob.
    ${ }^{\text {d }}$ Coordinates available at http://www.bionmr.chem.ed.ac.uk/bionmr/public_html/ccp-db.html
    ${ }^{\mathrm{e}}$ Solved in complex with heparin-derived octasaccharide.
    ${ }^{\mathrm{f}}$ Solved in complex with suramin.
    ${ }^{\mathrm{g}}$ This is the structure of intact factor B.
    ${ }^{\mathrm{h}}$ This structure also contains a protease domain.
    ${ }^{i}$ The fifth, C-terminal domain of $\beta 2$-GPI is CCP-like.
    ${ }^{j}$ The rat sequence was expressed for this structural work.
    ${ }^{\mathrm{k}}$ The first CCP is reported to be disordered.
    ${ }^{1}$ The mouse sequence was expressed for this structural work.
    ${ }^{m}$ Solved in complex with astressin.
    ${ }^{\mathrm{n}}$ This domain is CCP-like.
    ${ }^{0}$ This is the structure of IL-2-receptor $\alpha$-chain extracellular region complexed to IL-2 - the CCP-like domains are strand swapped.
    ${ }^{\mathrm{P}}$ Solved in complex with sucrose octasulfate.
    ${ }^{\mathrm{q}}$ Structure of IL-15-receptor $\alpha$-chain complexed to IL-15.
    ${ }^{\mathrm{r}}$ Solved in complex with intact C3b.
    ${ }^{5}$ Solved in complex with Neisseria meningitidis factor H binding protein.
    ${ }^{\mathrm{t}}$ Solved in complex with cobra venom factor (CVF).
    ${ }^{\mathrm{u}}$ The CRRY protein sequence is from rat (on hold in PDB).

